Giornale Italiano Di Dermatologia E Venereologia最新文献

{"title":"Correction to: Actinic keratoses: when and how to treat a single lesion.","authors":"Anna Carbone, Vitaliano Silipo, Laura Eibenschutz, Paolo Piemonte, Angela Ferrari, Pierluigi Buccini, Alessandra Iorio, Pasquale Frascione","doi":"10.23736/S0392-0488.21.06996-0","DOIUrl":"10.23736/S0392-0488.21.06996-0","url":null,"abstract":"<p><p>This corrects the article DOI: 10.23736/S0392-0488.18.06082-0.</p>","PeriodicalId":49071,"journal":{"name":"Giornale Italiano Di Dermatologia E Venereologia","volume":"155 6","pages":"808"},"PeriodicalIF":2.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25423868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Considerations on 18FDG PET/CT and sentinel lymph node biopsy in AJCC stages I and II of melanoma.","authors":"Giulia Veronesi,&nbsp;Giulia M Ravaioli,&nbsp;Martina Lambertini,&nbsp;Guido Zannetti,&nbsp;Stefania Diodato,&nbsp;Aldo Gardini,&nbsp;Annalisa Patrizi,&nbsp;Stefano Fanti,&nbsp;Emi Dika","doi":"10.23736/S0392-0488.18.06108-4","DOIUrl":"https://doi.org/10.23736/S0392-0488.18.06108-4","url":null,"abstract":"","PeriodicalId":49071,"journal":{"name":"Giornale Italiano Di Dermatologia E Venereologia","volume":"155 6","pages":"784-786"},"PeriodicalIF":2.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36307043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ixekizumab for treatment of moderate to severe plaque psoriasis: real world clinical experience.","authors":"Federico Diotallevi,&nbsp;Anna Campanati,&nbsp;Giulia Radi,&nbsp;Elisa Molinelli,&nbsp;Annamaria Offidani","doi":"10.23736/S0392-0488.18.06094-7","DOIUrl":"https://doi.org/10.23736/S0392-0488.18.06094-7","url":null,"abstract":"<p><strong>Background: </strong>Data concerning clinical experience in real world setting with ixekizumab for psoriasis are still exiguous. So, the aim of this report was to provide our experience in the use of ixekizumab in outpatient setting.</p><p><strong>Methods: </strong>Fifteen Caucasian individuals (10 male, 5 females; mean age: 58.1; range: 30-75 years) affected by moderate to severe plaque psoriasis (PASI≥10 and/or DLQI≥10 and/or BSA≥10) were treated with ixekizumab, following dosing regimen of technical data sheet and clinically evaluated after 4 weeks (T4) and 12 weeks (T12) after. At baseline median PASI was 16.3 (range: 10-30, SD=6.0). The median BSA was 21.3 (10-35, SD=7.0), the median PGA was 3.4 (2-6, SD=1.2), the median DLQI was 18.6 (14-25, SD=3.6), the median m-NAPSI was 42.0 (30-56, SD=13.11). The median absolute value of PASI, BSA, PGA, DLQI and m-NAPSI showed a statistically significant decrease (P<0.05) already after 4 weeks of treatment, in order to testify treatment effectiveness.</p><p><strong>Results: </strong>At T4, 93.3% of the patients reached PASI50, 6.9% reached PASI75; at T12, 100% of the patients reached PASI50, 80% reached PASI75, 13% reached PASI90 and 6.9% reached PASI100. One-third of observed patients reached MDA after 12 weeks of treatment. Injection site reactions were the only side effects occurring during the first 12 weeks of treatment.</p><p><strong>Conclusions: </strong>Our preliminary results seem to confirm the efficacy and safety profile provided through the UNCOVER pivotal trials (UNCOVER 1-3) although further larger observational studies are needed.</p>","PeriodicalId":49071,"journal":{"name":"Giornale Italiano Di Dermatologia E Venereologia","volume":"155 6","pages":"739-743"},"PeriodicalIF":2.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36665408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extramammary Paget disease of the vulva (VEMPD) with perianal involvement: a 30-year experience.","authors":"Francesco Sopracordevole,&nbsp;Jacopo DI Giuseppe,&nbsp;Giorgio Giorda,&nbsp;Lara Alessandrini,&nbsp;Vincenzo Canzonieri,&nbsp;Andrea Ciavattini","doi":"10.23736/S0392-0488.18.06186-2","DOIUrl":"https://doi.org/10.23736/S0392-0488.18.06186-2","url":null,"abstract":"","PeriodicalId":49071,"journal":{"name":"Giornale Italiano Di Dermatologia E Venereologia","volume":"155 6","pages":"804-806"},"PeriodicalIF":2.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36678971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ixekizumab in hidradenitis suppurativa in a psoriatic patient.","authors":"Giulia Odorici,&nbsp;Giovanni Pellacani,&nbsp;Andrea Conti","doi":"10.23736/S0392-0488.18.06135-7","DOIUrl":"https://doi.org/10.23736/S0392-0488.18.06135-7","url":null,"abstract":"","PeriodicalId":49071,"journal":{"name":"Giornale Italiano Di Dermatologia E Venereologia","volume":"155 6","pages":"788-789"},"PeriodicalIF":2.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36901410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An oral supplementation based on myo-inositol, folic acid and liposomal magnesium may act synergistically with antibiotic therapy and can improve metabolic profile in patients affected by Hidradenitis suppurativa: our experience.","authors":"Marianna Donnarumma,&nbsp;Claudio Marasca,&nbsp;Maria Palma,&nbsp;Maria Vastarella,&nbsp;Maria C Annunziata,&nbsp;Gabriella Fabbrocini","doi":"10.23736/S0392-0488.18.06012-1","DOIUrl":"https://doi.org/10.23736/S0392-0488.18.06012-1","url":null,"abstract":"<p><strong>Background: </strong>Over recent years, the link between obesity, metabolic syndrome and Hidradenitis suppurativa (HS) has been explored. It has been demonstrated that HS patients have a high prevalence of the metabolic syndrome and an increased frequency of insulin resistance. The objective of our study is to estimate the effectiveness of an oral supplementation based on myo-inositol (MI), folic acid and liposomal magnesium (Levigon^®, Sanitpharma; Milan, Italy) on the clinical and metabolic profile of patients affected by HS.</p><p><strong>Methods: </strong>Twenty subjects with HS and an impaired glucose metabolism were enrolled. Group A: 10 subjects received for 6 months MI 2000 mg, liposomal magnesium and folic acid associated to topical antibiotic therapy (clindamycin gel 1%), systemic antibiotic therapy (clindamycin 300 mg b.i.d. and rifampicin 600 mg daily for 6 weeks) and a normocaloric diet group B: 10 subjects received topical and systemic antibiotic therapy associated to a normocaloric diet for 6 months.</p><p><strong>Results: </strong>After 6 months group A patients showed an average reduction of Sartorius Score from 38.3±7.75 to 27.3±13.53 (P value <0.04) while in the control group there was a reduction of the Sartorius from 38.4±7.88 to 31.1±8.02 (P value =0.55). Moreover in group A Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) was significantly reduced from 2.43±0.35 to 2.1±0.31 (P<0.01) whereas in group B HOMA-IR did not significantly decrease (2.51±0.65 at T0 at 2.40±0.67 at T1).</p><p><strong>Conclusions: </strong>Our study underlines the importance of the evaluation of metabolic profile in patients with HS. Moreover, it suggests that the supplementation of MI, folic acid and liposomal magnesium in HS can improve the efficacy of concomitant therapies and the metabolic profile.</p>","PeriodicalId":49071,"journal":{"name":"Giornale Italiano Di Dermatologia E Venereologia","volume":"155 6","pages":"749-753"},"PeriodicalIF":2.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36520478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of key markers: IL-10/sHLA-G in psoriasis patients and the identification of 14-bp INDEL in the HLA-G gene.","authors":"M. Bieniek-Kobuszewska, Agnieszka Owczarczyk-Saczonek, Agata Maciejewska-Radomska, P. Wojtacha, W. Placek","doi":"10.23736/S0392-0488.20.06878-9","DOIUrl":"https://doi.org/10.23736/S0392-0488.20.06878-9","url":null,"abstract":"BACKGROUND\u0000Psoriasis is a chronic inflammation resulting from interactions between immunological and genetic factors. An important tolerogenic role in this autoimmunological disease is played by HLA-G, which is modulated by IL-10. Therefore, this study (N=80) aimed to evaluate changes in the serum sHLA-G and IL-10 levels in active psoriasis vulgaris and in the early stages of treatment with Methotrexate (MTX) compared to healthy controls. The 14-bp INDEL of the HLA-G gene was evaluated to find possible associations with clinical and laboratory variables.\u0000\u0000\u0000METHODS\u0000The level of sHLA-G and IL-10 in serum was evaluated (ELISA tests) in patients before the first dose of MTX and at week 12 of treatment, compared to healthy control donors. The 14-bp INDEL in 3'UTR of the HLA-G gene was identified using gDNA templates isolated from full blood. HLA-G amplicons were obtained by PCR, separated by electrophoresis and sequenced.\u0000\u0000\u0000RESULTS\u0000The mean serum IL-10 level was 4.653 ±3.33 pg/mL in psoriatic patients, 13.3 ± 9.64 pg/mL after short MTX treatment, compared to 6.23 pg/mL in healthy controls. In addition, the serum level of sHLA-G was 0.275± 0.03 ng/mL and 0.332 ± 0.06 ng/mL in patients before and after MTX treatment, respectively, and 0.302±0.08 ng/mL in the control group. A correlation was found (r= -0.43; p<0.005) between the IL-10 and BSA serum levels in psoriasis patients after MTX treatment, indicating health improvement. The three genotypes identified in the 3'UTR of the HLA-G revealed no association with sHLA-G level in serum.\u0000\u0000\u0000CONCLUSIONS\u0000The mean levels of sHLA-G and the key anti-inflammatory cytokine IL-10 in the blood of pre-treatment psoriasis patients are low and indicate that the immunotolerance mechanisms have failed. Treatment of psoriasis patients with low systemic levels of sHLA-G and IL-10 brings them to the same or higher protein levels, respectively, as in healthy donors. Higher sHLA-G levels in healthy donors and after MTX treatment, compared to the sHLA-G levels in the acute phase of psoriasis, indicates its immune system surveillance function.","PeriodicalId":49071,"journal":{"name":"Giornale Italiano Di Dermatologia E Venereologia","volume":"31 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76471384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A small blackberry-like nodule on the nipple in a pregnant affected by tuberous sclerosis complex.","authors":"Carmelo Schepis,&nbsp;Maddalena Siragusa,&nbsp;Maria Bottitta,&nbsp;Maria Lentini","doi":"10.23736/S0392-0488.19.06174-1","DOIUrl":"https://doi.org/10.23736/S0392-0488.19.06174-1","url":null,"abstract":"","PeriodicalId":49071,"journal":{"name":"Giornale Italiano Di Dermatologia E Venereologia","volume":"155 6","pages":"799-800"},"PeriodicalIF":2.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36976418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reticulated erythema of the breast: a case of intravascular histiocytosis with hemophagocytosis.","authors":"Enzo Palese,&nbsp;Vincenzo Panasiti,&nbsp;Rosa Coppola,&nbsp;Maurizio Nudo,&nbsp;Grazia Zino,&nbsp;Giorgio Annessi","doi":"10.23736/S0392-0488.19.06162-5","DOIUrl":"https://doi.org/10.23736/S0392-0488.19.06162-5","url":null,"abstract":"","PeriodicalId":49071,"journal":{"name":"Giornale Italiano Di Dermatologia E Venereologia","volume":"155 6","pages":"796-798"},"PeriodicalIF":2.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37101283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lack of detection of Cutavirus DNA using PCR real time in cutaneous T-cell lymphomas.","authors":"Massimiliano Bergallo,&nbsp;Valentina DaprÀ,&nbsp;Paolo Fava,&nbsp;Renata Ponti,&nbsp;Cristina Calvi,&nbsp;Maria T Fierro,&nbsp;Pietro Quaglino,&nbsp;Ilaria Galliano,&nbsp;Paola Montanari","doi":"10.23736/S0392-0488.18.06161-8","DOIUrl":"https://doi.org/10.23736/S0392-0488.18.06161-8","url":null,"abstract":"<p><strong>Background: </strong>A novel human protoparvovirus named Cutavirus has been discovered. We investigated the presence of Cutavirus in a sample of Cutaneous T-cell lymphomas by using PCR real time TaqMan® (Thermo Fisher Scientific, Waltham, MA, USA).</p><p><strong>Methods: </strong>In total, 55 CTCL samples were analyzed using a TaqMan® Real time PCR on a 7500 ABI instrument. All of these shown internal control amplification.</p><p><strong>Results: </strong>The presence of Cutavirus DNA corresponding was examined. CuV DNA sequences were not detected in any skin specimen.</p><p><strong>Conclusions: </strong>The role of Cutaviruses in cutaneous cancers remains to be investigated.</p>","PeriodicalId":49071,"journal":{"name":"Giornale Italiano Di Dermatologia E Venereologia","volume":"155 6","pages":"772-774"},"PeriodicalIF":2.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36618820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}